Target validation and functional analyses using antisense oligonucleotides

Bibliography

• ZAMECNIK P, STEPHENSON M: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sd. USA (1978) 1:280–284.
   Google Scholar
• STEPHENSON M, ZAMECNIK P: Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Nati Acad. Sci. USA (1978) 75:285–288.
   PubMed Web of Science ®Google Scholar
• WOOLF TM, MELTON DA, JENNINGS CGB: Specificity of antisense oligonucleotides in vivo. Proc. Nati Acad. Sci. USA (1992) 89:7305–7309.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, ZHAO Q: Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Add Drug Dev (1998) 8:135–139.
   PubMedGoogle Scholar
• MCKAY RA, CUMMINS LL, GRAHAM MJ et al.: Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2'-0-propyl modifications. Nucleic Adds Res. (1996) 24:411–417.
   PubMed Web of Science ®Google Scholar
• MONIA BP, LESNIK EA, GONZALEZ C et al.: Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. Biol. Chem. (1993) 268:14514–14522.
   Web of Science ®Google Scholar
• ••This is a classic antisense paper thatprovides a carefully controlled evaluation of 2'-modified oligonucleotides and demonstrates the importance of target affinity and RNase H mechanism of action for antisense efficacy.
   Google Scholar
• GILES RV, SPILLER DG, GRYZBOWSKI J et al.: Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin 0-mediated delivery into human leukaemia cells. Nucleic Acids Res. (1998) 26:1567–1575.
   PubMed Web of Science ®Google Scholar
• MCKAY RA, MIRAGLIA LJ, CUMMINS LL et al.: Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J. Biol. Chem. (1999) 274:1715–1722.
   PubMed Web of Science ®Google Scholar
• XU XS, VANDERZIEL C, BENNETT CEMONIA BP: A role for c-Raf kinase and Ha-Ras in cytokine-mediated induction of cell adhesion molecules. j Biol. Chem. (1998) 273:33230–33238.
   PubMed Web of Science ®Google Scholar
• VASSAR R, BENNETT BD, SAFURA B- K et al.: Beta-secretase cleavage of Alzheimer's protein by the transmembrane aspartic protease BASE. Science (1999) 286:735–741.
   Google Scholar
• •The authors demonstrated the improved efficacy of 2'-0-modified antisense oligonucleotides, as compared with standard phosphorothioate oligonucleotides. The data also demonstrate the specific inhibition of the a isoform of PKC.
   Google Scholar
• YAN R, BIENKOWSKI MJ, SHUCK ME et al.: Membrane-anchored aspartyl potease with Alheimer's disease Beta-secretase activity. Nature (1999) 402:533–537.
   PubMed Web of Science ®Google Scholar
• •The utility of antisense technology in the process of discovery and validation of new drug targets is clearly demonstrated.
   Google Scholar
• BENNETT CF: Antisense oligonucleotides: is the glass half full or half empty? Biochem. Pharmacol. (1998) 55:9–19.
   Web of Science ®Google Scholar
• FLANAGAN WM, WOLF JJ, OLSON P et al.: A cytosine analog that confers enhanced potency to antisense oligonucleotides. Proc. Natl. Acad. Li. USA (1999) 96:3513–3518.
   PubMed Web of Science ®Google Scholar
• WAHLESTEDT C, SALMI P, GOOD L et al.: Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. USA (2000) 97:5633–5638.
   PubMed Web of Science ®Google Scholar
• NIELSEN PE, EGHOLM M, BUCHARDT 0: Peptide nucleic acid (PNA). A DNA mimic with a peptide backbone. Bioconjugate Chem. (1994) 5:3–7.
   PubMed Web of Science ®Google Scholar
• SUMMERTON J, WELLER D: Morpholino antisense oligomers: design, preparation and properties. Antisense Nucleic Add Drug Dev (1997) 7:187–195.
   PubMedGoogle Scholar
• NASEVICIUS A, EKKER SC: Effective targeted gene 'knockdown' in zebrafish. Nature Genetics (2000) 26:216–220.
   PubMed Web of Science ®Google Scholar
• HEASMAN J, KOFRON M, WYLIE C: B catenin signaling activity dissected in the early embryo: a novel antisense approach. Developmental Biol. (2000) 222:124–134.
   PubMed Web of Science ®Google Scholar
• WAGNER RW, MATTEUCCI MD, GRANT D, HUANG T, FROEHLER BC: Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nature Biotechnol. (1996) 14:840–844.
   PubMed Web of Science ®Google Scholar
• POTAPOVA O, GOROSPE M, DOUGHERTY RH et al.: Inhibition of c-jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p-53 dependent manner. Molecular Cellular Biol. (2000) 20:1713–1722.
   PubMed Web of Science ®Google Scholar
• KOLLER E, GAARDE WA, MONIA BP: Elucidating cell signaling mechanisms using antisense technology. Trends Pharmacol. Sci. (2000) 4:142–148.
   Google Scholar
• ••This is an excellent review of the use of antisense oligonucleotides to elucidate signal transduction pathways. The authors provide a comparison of antisense technology with other technologies that have been used to study such pathways.
   Google Scholar
• COLLINS FS, PATRINOS A, JORDAN E et al.: New goals for the US human genome project: 1998-2003. Science (1998) 282:682–689.
   PubMed Web of Science ®Google Scholar
• REBHAN M, CHALIFA-CASPI V, PRILUSKY J, LANCET D: GeneCards: a novel functional genomics compendium with automated data mining and query reformulation support. Bioinformatics. (1998) 14:656–664.
   PubMed Web of Science ®Google Scholar
• RASTAN SBEELEY LJ: Functional genomics: going forward from the databases. Curr. Opin Genet. Dev. (1997) 7:777–783.
   PubMed Web of Science ®Google Scholar
• TORTORA G, CAPUTO R, DAMIANO V et al.: Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents. Antisense Nucleic Acid Drug Dev (1998) 8:141–145.
   PubMedGoogle Scholar
• LUO Y, BOLON B, KAHN S et al.: Micedeficient in BACE1, the Alzheimer's beta- secretase, have normal phenotype and abolished beta-amyloid generation. Nature Neurosci. (2001) 4:231–232.
   PubMed Web of Science ®Google Scholar
• BOST F, MCKAY R, DEAN N, MERCOLA D: The JUN kinaseistress-activated protein kiase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells. j Biol. Chem. (1997) 272:33422–33429.
   PubMed Web of Science ®Google Scholar
• ZIEGLER A, LEUDKE GH, FABBRO D et al.: Induction of apoptosis an small-cell lung cancer cells by an antisense oligodeoxyncleotide targeting the Bc1-2 coding sequence. I Natl. Cancer Inst. (1997) 89:1027–1036.
   PubMed Web of Science ®Google Scholar
• STANCHEVA IMEEHAN RR: Transient depletion of xDmntl leads to premature gene activation in xenopus embryos. Genes Devel. (2000) 14:313–327.
   PubMed Web of Science ®Google Scholar
• KARRAS JG, MCGRAW K, MCKAY RA et al.: Inhibition of antigen-induced eosinophilia and late phase airway hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse models of asthma. Immunology (2000) 164:5409–5415.
   Web of Science ®Google Scholar
• ARORA V, KNAPP DC, SMITH BL et al.: c-Myc antisense limits rat liver regeneration and indicates role for c-myc in cytochrome p450 3A activity. I Pharmacol. Exp. Therapeutics. (2000) 292:921–928.
   PubMed Web of Science ®Google Scholar
• ZHANG H, COOK J, NICKEL J et al.: Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nature Biotech. (2000) 18:862–867.
   PubMed Web of Science ®Google Scholar
• BRANCH AD: A good antisense molecule is hard to find. Trends Biol. Sci (1998) 23:45–50.
   PubMed Web of Science ®Google Scholar